Plain-English translation of NCT05508035 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether sacubitril/valsartan, a newer heart failure medication, works better than , a standard heart medication, for people whose hearts don't pump as strongly as they should after a heart attack. The study will measure whether the medication can help the heart work better and prevent further damage over 12 months.
Doctors know this medication helps people with more severely weakened hearts, but they don't yet know if it also helps people like you whose hearts are only moderately weakened. This study will answer that important question.
You likely qualify if…
You likely don't qualify if…
You will first take for a few weeks to see how well you tolerate it, then take the newer medication for a few weeks to make sure that works too. If both go well, you'll be randomly assigned to take either the newer medication or twice daily for 12 months. During this time, you'll have regular visits with the study team, blood tests, and heart imaging scans (MRI) to measure how your heart is responding to treatment.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
Poland